Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
New study questions role of persistent gene activity in memory maintenance
An experiment in sea slugs suggests transcriptional changes might fade after 24 hours.
New study questions role of persistent gene activity in memory maintenance
An experiment in sea slugs suggests transcriptional changes might fade after 24 hours.
Tracking health in autistic adults, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 April.
Tracking health in autistic adults, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 April.
Can AI do neuroscience without understanding?
Prediction without understanding sustained astronomy through a thousand years of epicycles. Artificial intelligence is now offering neuroscience the same deal.
Can AI do neuroscience without understanding?
Prediction without understanding sustained astronomy through a thousand years of epicycles. Artificial intelligence is now offering neuroscience the same deal.